Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of ...

Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...

The Dow Jones rose Thursday after surprise weekly jobless claims. Nvidia partner Arm stock tumbled on earnings, while Roblox ...

Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Eli Lilly stock rose Thursday despite lighter-than-expected sales of its weight-loss and diabetes drugs Zepbound and Mounjaro ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

Investing.com - Eli Lilly's full-year profit forecast largely surpassed Wall Street expectations on Thursday, as the ...

Ford (NYSE: F) stock fell 5.5% after the auto giant forecast weaker annual profit at a time when the threat of US tariffs on ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Investing.com--US stocks edged higher Thursday, as investors assessed a deluge of corporate earnings as well as more labor market data. At 09:45 ET (14:45 GMT), the Dow Jones Industrial Average rose ...

China, one of the countries affected by the new tariffs, is the world’s largest producer of active pharmaceutical ingredients ...